Upload File

sensititre gn2f plate worksheettools.thermofisher.com/content/sfs/brochures... · tim2 64/2 axo 1...

  • Home
  • Documents
  • Sensititre GN2F Plate Worksheettools.thermofisher.com/content/sfs/brochures... · tim2 64/2 axo 1 fox 8 amp 4 amp 8 faz 32 gat 8 imi 16 2 nit 128 imi 2 sxt 4/76 tim2 16/2 pos pos
3
AMI -- Amikacin AMP -- Ampicillin A/S2 -- Ampicillin/sulbactam 2:1 ratio AZT -- Aztreonam FAZ -- Cefazolin FEP -- Cefepime TANS -- Cefotetan Na AXO -- Ceftriaxone TAZ -- Ceftazidime FOX -- Cefoxitin POD -- Cefpodoxime FUR -- Cefuroxime CIP -- Ciprofloxacin IMI -- Imipenem GAT -- Gatifloxacin GEN -- Gentamicin MERO -- Meropenem NIT -- Nitrofurantoin PIP -- Piperacillin P/T4 -- Piperacillin/tazobactam constant 4 TIM2 -- Ticarcillin/clavulanic acid constant 2 TOB -- Tobramycin SXT -- Trimethoprim/sulfamethoxazole POS -- Positive Control NEG -- Negative Control AMI -- Amikacin AMP -- Ampicillin A/S2 -- Ampicillin/sulbactam 2:1 ratio AZT -- Aztreonam FAZ -- Cefazolin FEP -- Cefepime TANS -- Cefotetan Na AXO -- Ceftriaxone TAZ -- Ceftazidime FOX -- Cefoxitin POD -- Cefpodoxime FUR -- Cefuroxime CIP -- Ciprofloxacin IMI -- Imipenem GAT -- Gatifloxacin GEN -- Gentamicin MERO -- Meropenem NIT -- Nitrofurantoin PIP -- Piperacillin P/T4 -- Piperacillin/tazobactam constant 4 TIM2 -- Ticarcillin/clavulanic acid constant 2 TOB -- Tobramycin SXT -- Trimethoprim/sulfamethoxazole POS -- Positive Control NEG -- Negative Control GN2F Date: Patient Name: Lot #: Isolate #: Technician: Signature: GN2F -- WS GN2F Date: Patient Name: Lot #: Isolate #: Technician: Signature: GN2F -- WS No Interpretation Non-Susceptible Susceptible Intermediate Resistant Non-Susceptible Susceptible Intermediate Resistant No Interpretation FDA Interpretive Criteria Enterobacteriaceae 1 2 3 4 5 6 7 8 9 10 11 12 FDA Interpretive Criteria Non-Enterobacteriaceae 1 2 3 4 5 6 7 8 9 10 11 12 AMP 4 AMP 8 FAZ 32 GAT 8 IMI 16 GEN 2 NIT 128 IMI 2 SXT 4/76 TIM2 16/2 POS POS NEG POD 2 POD 8 POD 16 TOB 4 SXT 0.5/9.5 SXT 1/19 TIM2 32/2 POS P/T4 16/4 P/T4 32/4 P/T4 64/4 P/T4 128/4 PIP 16 PIP 32 PIP 128 FOX 16 FOX 32 NIT 16 NIT 32 IMI 4 GEN 4 GEN 16 MERO 1 MERO 2 MERO 4 GAT 1 GAT 2 CIP 0.5 CIP 1 CIP 2 CIP 4 FUR 4 FUR 8 FUR 32 TAZ 1 TAZ 2 TAZ 4 TAZ 8 TAZ 16 TAZ 32 AXO 2 AXO 4 AXO 8 AXO 16 AXO 32 AXO 64 TANS 8 TANS 32 FEP 4 FEP 8 FEP 16 FEP 32 FAZ 4 FAZ 8 AZT 8 AZT 16 AZT 32 A/S2 4/2 A/S2 8/4 A/S2 16/8 AMP 16 AMP 32 AMI 8 AMI 16 AMI 32 A/S2 32/16 IMI 8 NIT 64 SXT 2/38 TOB 8 AMI 64 FAZ 16 FUR 16 GAT 4 GEN 8 PIP 64 FOX 4 POD 4 TANS 16 TIM2 64/2 AXO 1 FOX 8 AMP 4 AMP 8 FAZ 32 GAT 8 IMI 16 GEN 2 NIT 128 IMI 2 SXT 4/76 TIM2 16/2 POS POS NEG POD 2 POD 8 POD 16 TOB 4 SXT 0.5/9.5 SXT 1/19 TIM2 32/2 POS P/T4 16/4 P/T4 32/4 P/T4 64/4 P/T4 128/4 PIP 16 PIP 32 PIP 128 FOX 16 FOX 32 NIT 16 NIT 32 IMI 4 GEN 4 GEN 16 MERO 1 MERO 2 MERO 4 MERO 8 GAT 1 GAT 2 CIP 0.5 CIP 1 CIP 2 CIP 4 FUR 4 FUR 8 FUR 32 TAZ 1 TAZ 2 TAZ 4 TAZ 8 TAZ 16 TAZ 32 AXO 2 AXO 4 AXO 8 AXO 16 AXO 32 AXO 64 TANS 8 TANS 32 FEP 4 FEP 8 FEP 16 FEP 32 FAZ 4 FAZ 8 AZT 8 AZT 16 AZT 32 A/S2 4/2 A/S2 8/4 A/S2 16/8 AMP 16 AMP 32 AMI 8 AMI 16 AMI 32 A/S2 32/16 IMI 8 NIT 64 SXT 2/38 TOB 8 AMI 64 FAZ 16 FUR 16 GAT 4 GEN 8 PIP 64 FOX 4 POD 4 TANS 16 TIM2 64/2 AXO 1 FOX 8 MERO 8 ® ®

Upload: others

Post on 31-Jan-2021

0 views

Category:

Documents


0 download

Report

TRANSCRIPT

  • AMI -- AmikacinAMP -- AmpicillinA/S2 -- Ampicillin/sulbactam 2:1 ratioAZT -- AztreonamFAZ -- CefazolinFEP -- CefepimeTANS -- Cefotetan NaAXO -- CeftriaxoneTAZ -- CeftazidimeFOX -- CefoxitinPOD -- CefpodoximeFUR -- CefuroximeCIP -- CiprofloxacinIMI -- Imipenem GAT -- GatifloxacinGEN -- GentamicinMERO -- MeropenemNIT -- NitrofurantoinPIP -- PiperacillinP/T4 -- Piperacillin/tazobactam constant 4TIM2 -- Ticarcillin/clavulanic acid constant 2TOB -- TobramycinSXT -- Trimethoprim/sulfamethoxazolePOS -- Positive ControlNEG -- Negative Control

    AMI -- AmikacinAMP -- AmpicillinA/S2 -- Ampicillin/sulbactam 2:1 ratioAZT -- AztreonamFAZ -- CefazolinFEP -- CefepimeTANS -- Cefotetan NaAXO -- CeftriaxoneTAZ -- CeftazidimeFOX -- CefoxitinPOD -- CefpodoximeFUR -- CefuroximeCIP -- CiprofloxacinIMI -- Imipenem GAT -- GatifloxacinGEN -- GentamicinMERO -- MeropenemNIT -- NitrofurantoinPIP -- PiperacillinP/T4 -- Piperacillin/tazobactam constant 4TIM2 -- Ticarcillin/clavulanic acid constant 2TOB -- TobramycinSXT -- Trimethoprim/sulfamethoxazolePOS -- Positive ControlNEG -- Negative Control

    GN2FDate: Patient Name: Lot #:

    Isolate #: Technician: Signature:

    GN2F -- WS

    GN2FDate: Patient Name: Lot #:

    Isolate #: Technician: Signature:

    GN2F -- WS

    No InterpretationNon-SusceptibleSusceptible Intermediate Resistant

    Non-SusceptibleSusceptible Intermediate Resistant No Interpretation

    FDA Interpretive Criteria Enterobacteriaceae

    1 2 3 4 5 6 7 8 9 10 11 12

    FDA Interpretive Criteria Non-Enterobacteriaceae

    1 2 3 4 5 6 7 8 9 10 11 12

    AMP4

    AMP8

    FAZ32

    GAT8

    IMI16

    GEN2

    NIT128

    IMI2

    SXT4/76

    TIM216/2

    POS POS

    NEG

    POD2

    POD8

    POD16

    TOB4

    SXT0.5/9.5

    SXT1/19

    TIM232/2

    POS

    P/T416/4

    P/T432/4

    P/T464/4

    P/T4128/4

    PIP16

    PIP32

    PIP128

    FOX16

    FOX32

    NIT16

    NIT32

    IMI4

    GEN4

    GEN16

    MERO1

    MERO2

    MERO4

    GAT1

    GAT2

    CIP0.5

    CIP1

    CIP2

    CIP4

    FUR4

    FUR8

    FUR32

    TAZ1

    TAZ2

    TAZ4

    TAZ8

    TAZ16

    TAZ32

    AXO2

    AXO4

    AXO8

    AXO16

    AXO32

    AXO64

    TANS8

    TANS32

    FEP4

    FEP8

    FEP16

    FEP32

    FAZ4

    FAZ8

    AZT8

    AZT16

    AZT32

    A/S24/2

    A/S28/4

    A/S216/8

    AMP16

    AMP32

    AMI8

    AMI16

    AMI32

    A/S232/16

    IMI8

    NIT64

    SXT2/38

    TOB8

    AMI64

    FAZ16

    FUR16

    GAT4

    GEN8

    PIP64

    FOX4

    POD4

    TANS16

    TIM264/2

    AXO1

    FOX8

    AMP4

    AMP8

    FAZ32

    GAT8

    IMI16

    GEN2

    NIT128

    IMI2

    SXT4/76

    TIM216/2

    POS POS

    NEG

    POD2

    POD8

    POD16

    TOB4

    SXT0.5/9.5

    SXT1/19

    TIM232/2

    POS

    P/T416/4

    P/T432/4

    P/T464/4

    P/T4128/4

    PIP16

    PIP32

    PIP128

    FOX16

    FOX32

    NIT16

    NIT32

    IMI4

    GEN4

    GEN16

    MERO1

    MERO2

    MERO4

    MERO8

    GAT1

    GAT2

    CIP0.5

    CIP1

    CIP2

    CIP4

    FUR4

    FUR8

    FUR32

    TAZ1

    TAZ2

    TAZ4

    TAZ8

    TAZ16

    TAZ32

    AXO2

    AXO4

    AXO8

    AXO16

    AXO32

    AXO64

    TANS8

    TANS32

    FEP4

    FEP8

    FEP16

    FEP32

    FAZ4

    FAZ8

    AZT8

    AZT16

    AZT32

    A/S24/2

    A/S28/4

    A/S216/8

    AMP16

    AMP32

    AMI8

    AMI16

    AMI32

    A/S232/16

    IMI8

    NIT64

    SXT2/38

    TOB8

    AMI64

    FAZ16

    FUR16

    GAT4

    GEN8

    PIP64

    FOX4

    POD4

    TANS16

    TIM264/2

    AXO1

    FOX8

    MERO8

    ®

    ®

  • AMI -- AmikacinAMP -- AmpicillinA/S2 -- Ampicillin/sulbactam 2:1 ratioAZT -- AztreonamFAZ -- CefazolinFEP -- CefepimeTANS -- Cefotetan NaAXO -- CeftriaxoneTAZ -- CeftazidimeFOX -- CefoxitinPOD -- CefpodoximeFUR -- CefuroximeCIP -- CiprofloxacinIMI -- Imipenem GAT -- GatifloxacinGEN -- GentamicinMERO -- MeropenemNIT -- NitrofurantoinPIP -- PiperacillinP/T4 -- Piperacillin/tazobactam constant 4TIM2 -- Ticarcillin/clavulanic acid constant 2TOB -- TobramycinSXT -- Trimethoprim/sulfamethoxazolePOS -- Positive ControlNEG -- Negative Control

    GN2FDate: Patient Name: Lot #:

    Isolate #: Technician: Signature:

    GN2F -- WS

    Quality Control Ranges Escherichia coli ATCC 25922

    1 2 3 4 5 6 7 8 9 10 11 12

    AMI -- AmikacinAMP -- AmpicillinA/S2 -- Ampicillin/sulbactam 2:1 ratioAZT -- AztreonamFAZ -- CefazolinFEP -- CefepimeTANS -- Cefotetan NaAXO -- CeftriaxoneTAZ -- CeftazidimeFOX -- CefoxitinPOD -- CefpodoximeFUR -- CefuroximeCIP -- CiprofloxacinIMI -- Imipenem GAT -- GatifloxacinGEN -- GentamicinMERO -- MeropenemNIT -- NitrofurantoinPIP -- PiperacillinP/T4 -- Piperacillin/tazobactam constant 4TIM2 -- Ticarcillin/clavulanic acid constant 2TOB -- TobramycinSXT -- Trimethoprim/sulfamethoxazolePOS -- Positive ControlNEG -- Negative Control

    GN2FDate: Patient Name: Lot #:

    Isolate #: Technician: Signature:

    GN2F -- WS

    FDA Interpretive Criteria Pseudomonas aeruginosa

    1 2 3 4 5 6 7 8 9 10 11 12

    No InterpretationNon-SusceptibleSusceptible Intermediate Resistant

    AMP4

    AMP8

    FAZ32

    GAT8

    IMI16

    GEN2

    NIT128

    IMI2

    SXT4/76

    TIM216/2

    POS POS

    NEG

    POD2

    POD8

    POD16

    TOB4

    SXT0.5/9.5

    SXT1/19

    TIM232/2

    POS

    P/T416/4

    P/T432/4

    P/T464/4

    P/T4128/4

    PIP16

    PIP32

    PIP128

    FOX16

    FOX32

    NIT16

    NIT32

    IMI4

    GEN4

    GEN16

    MERO1

    MERO2

    MERO4

    MERO8

    GAT1

    GAT2

    CIP0.5

    CIP1

    CIP2

    CIP4

    FUR4

    FUR8

    FUR32

    TAZ1

    TAZ2

    TAZ4

    TAZ8

    TAZ16

    TAZ32

    AXO2

    AXO4

    AXO8

    AXO16

    AXO32

    AXO64

    TANS8

    TANS32

    FEP4

    FEP8

    FEP16

    FEP32

    FAZ4

    FAZ8

    AZT8

    AZT16

    AZT32

    A/S24/2

    A/S28/4

    A/S216/8

    AMP16

    AMP32

    AMI8

    AMI16

    AMI32

    A/S232/16

    IMI8

    NIT64

    SXT2/38

    TOB8

    AMI64

    FAZ16

    FUR16

    GAT4

    GEN8

    PIP64

    FOX4

    POD4

    TANS16

    TIM264/2

    AXO1

    FOX8

    AMP4

    AMP8

    FAZ32

    GAT8

    IMI16

    GEN2

    NIT128

    IMI2

    SXT4/76

    TIM216/2

    POS POS

    NEG

    POD2

    POD8

    POD16

    TOB4

    SXT0.5/9.5

    SXT1/19

    TIM232/2

    POS

    P/T416/4

    P/T432/4

    P/T464/4

    P/T4128/4

    PIP16

    PIP32

    PIP128

    FOX16

    FOX32

    NIT16

    NIT32

    IMI4

    GEN4

    GEN16

    MERO1

    MERO2

    MERO4

    MERO8

    GAT1

    GAT2

    CIP0.5

    CIP1

    CIP2

    CIP4

    FUR4

    FUR8

    FUR32

    TAZ1

    TAZ2

    TAZ4

    TAZ8

    TAZ16

    TAZ32

    AXO2

    AXO4

    AXO8

    AXO16

    AXO32

    AXO64

    TANS8

    TANS32

    FEP4

    FEP8

    FEP16

    FEP32

    FAZ4

    FAZ8

    AZT8

    AZT16

    AZT32

    A/S24/2

    A/S28/4

    A/S216/8

    AMP16

    AMP32

    AMI8

    AMI16

    AMI32

    A/S232/16

    IMI8

    NIT64

    SXT2/38

    TOB8

    AMI64

    FAZ16

    FUR16

    GAT4

    GEN8

    PIP64

    FOX4

    POD4

    TANS16

    TIM264/2

    AXO1

    FOX8

    Quality Control Range

    ®

    ®

  • AMI -- AmikacinAMP -- AmpicillinA/S2 -- Ampicillin/sulbactam 2:1 ratioAZT -- AztreonamFAZ -- CefazolinFEP -- CefepimeTANS -- Cefotetan NaAXO -- CeftriaxoneTAZ -- CeftazidimeFOX -- CefoxitinPOD -- CefpodoximeFUR -- CefuroximeCIP -- CiprofloxacinIMI -- Imipenem GAT -- GatifloxacinGEN -- GentamicinMERO -- MeropenemNIT -- NitrofurantoinPIP -- PiperacillinP/T4 -- Piperacillin/tazobactam constant 4TIM2 -- Ticarcillin/clavulanic acid constant 2TOB -- TobramycinSXT -- Trimethoprim/sulfamethoxazolePOS -- Positive ControlNEG -- Negative Control

    GN2FDate: Patient Name: Lot #:

    Isolate #: Technician: Signature:

    GN2F -- WS

    Quality Control Ranges Escherichia coli ATCC 35218

    1 2 3 4 5 6 7 8 9 10 11 12

    AMI -- AmikacinAMP -- AmpicillinA/S2 -- Ampicillin/sulbactam 2:1 ratioAZT -- AztreonamFAZ -- CefazolinFEP -- CefepimeTANS -- Cefotetan NaAXO -- CeftriaxoneTAZ -- CeftazidimeFOX -- CefoxitinPOD -- CefpodoximeFUR -- CefuroximeCIP -- CiprofloxacinIMI -- Imipenem GAT -- GatifloxacinGEN -- GentamicinMERO -- MeropenemNIT -- NitrofurantoinPIP -- PiperacillinP/T4 -- Piperacillin/tazobactam constant 4TIM2 -- Ticarcillin/clavulanic acid constant 2TOB -- TobramycinSXT -- Trimethoprim/sulfamethoxazolePOS -- Positive ControlNEG -- Negative Control

    GN2FDate: Patient Name: Lot #:

    Isolate #: Technician: Signature:

    GN2F -- WS

    Quality Control Ranges Pseudomonas aeruginosa ATCC 27853

    Quality Control Range

    1 2 3 4 5 6 7 8 9 10 11 12

    AMP4

    AMP8

    FAZ32

    GAT8

    IMI16

    GEN2

    NIT128

    IMI2

    SXT4/76

    TIM216/2

    POS POS

    NEG

    POD2

    POD8

    POD16

    TOB4

    SXT0.5/9.5

    SXT1/19

    TIM232/2

    POS

    P/T416/4

    P/T432/4

    P/T464/4

    P/T4128/4

    PIP16

    PIP32

    PIP128

    FOX16

    FOX32

    NIT16

    NIT32

    IMI4

    GEN4

    GEN16

    MERO1

    MERO2

    MERO4

    MERO8

    GAT1

    GAT2

    CIP0.5

    CIP1

    CIP2

    CIP4

    FUR4

    FUR8

    FUR32

    TAZ1

    TAZ2

    TAZ4

    TAZ8

    TAZ16

    TAZ32

    AXO2

    AXO4

    AXO8

    AXO16

    AXO32

    AXO64

    TANS8

    TANS32

    FEP4

    FEP8

    FEP16

    FEP32

    FAZ4

    FAZ8

    AZT8

    AZT16

    AZT32

    A/S24/2

    A/S28/4

    A/S216/8

    AMP16

    AMP32

    AMI8

    AMI16

    AMI32

    A/S232/16

    IMI8

    NIT64

    SXT2/38

    TOB8

    AMI64

    FAZ16

    FUR16

    GAT4

    GEN8

    PIP64

    FOX4

    POD4

    TANS16

    TIM264/2

    AXO1

    FOX8

    AMP4

    AMP8

    FAZ32

    GAT8

    IMI16

    GEN2

    NIT128

    IMI2

    SXT4/76

    TIM216/2

    POS POS

    NEG

    POD2

    POD8

    POD16

    TOB4

    SXT0.5/9.5

    SXT1/19

    TIM232/2

    POS

    P/T416/4

    P/T432/4

    P/T464/4

    P/T4128/4

    PIP16

    PIP32

    PIP128

    FOX16

    FOX32

    NIT16

    NIT32

    IMI4

    GEN4

    GEN16

    MERO1

    MERO2

    MERO4

    MERO8

    GAT1

    GAT2

    CIP0.5

    CIP1

    CIP2

    CIP4

    FUR4

    FUR8

    FUR32

    TAZ1

    TAZ2

    TAZ4

    TAZ8

    TAZ16

    TAZ32

    AXO2

    AXO4

    AXO8

    AXO16

    AXO32

    AXO64

    TANS8

    TANS32

    FEP4

    FEP8

    FEP16

    FEP32

    FAZ4

    FAZ8

    AZT8

    AZT16

    AZT32

    A/S24/2

    A/S28/4

    A/S216/8

    AMP16

    AMP32

    AMI8

    AMI16

    AMI32

    A/S232/16

    IMI8

    NIT64

    SXT2/38

    TOB8

    AMI64

    FAZ16

    FUR16

    GAT4

    GEN8

    PIP64

    FOX4

    POD4

    TANS16

    TIM264/2

    AXO1

    FOX8

    Quality Control Range

    ®

    ®


Phase Change Metallic Alloy TIM2 Performance, Reliability ...indigo-xtreme.com/docs/atw_presentation_2007.pdfPhase Change Metallic Alloy TIM2 Performance, Reliability and Deployment

IMI Questions Lists specific issues related to IMI PQ

IMI rules and procedures - Guvernul Romaniei · Fabrizio Federici 02.12.2014 IMI 2 Open Info Day Bucharest, Rumania IMI rules and procedures

IMI STI - IMI Critical Engineering · IMI STI IMI STI is an international leader in valve actuation. Our products are designed for use in the most severe service applications (valves,

IMI - Stationmix BM

Rules and Procedures for IMI Calls for proposals · 2018-04-27 · Rules and Procedures for IMI Calls for proposals IMI Webinar • 17 July 2017. 1. Introducing IMI 2. ... Use of

The IMI project IMI-PharmaTrain harmonized educational

AOfOMN - qone Pos. Pos. Aee: Pos. 411 Pos. Pos. Pos. 01+9 ...dssg.awimedia.net/media/0/6/7/6142_175067_208935... · AOfOMN - qone Pos. Pos. Aee: Pos. 411 Pos. Pos. Pos. 01+9 LN0 Pos

IMI Education and training Projects · 2018. 4. 27. · IMI EducatIon and traInIng PrograMMEs European Medicines Research ... IMI continuing Professional development IMI Education

IMI - Kolkata

IMI ACADEMY

PRODUCT CATALOGUE-IMI

From IMI to IMI2 · in Life Science aiming to: ... The IMI portfolio . IMI2 . The evolution of IMI: ... IMI 2 includes real life medical practice 2013 SRA . Strategic Research Agenda

Rules and Procedures for IMI Calls for proposals · Rules and Procedures for IMI Calls for proposals IMI Webinar • 25 April 2016 How to use GoToWebinar – Catherine Brett, IMI

XZZ-TIM2 2.4 GHz IEEE 802.15.4 and ZigBee Module · XZZ-TIM2 is a low power IEEE 802.15.4, ZigBee and RF4CE module based on TI CC2530F256 and a power amplifier RFX2401C. This module

Partner presentation (imi)

Project IMI

TRAINER GUIDE - IMI

IMI presenatation

International Management Institute, IMI New Delhi, IMI

IMI plc · 2020. 2. 14. · IMI Precision Engineering’s end markets offsetting ongoing softness in the Energy markets in IMI Critical Engineering. ... embedded in ten of IMI Critical

100DMT - IMI Critical

IMI May, 2013

0Day2b TIM2 Guide - Eindhoven University of Technologyheco/courses/PlatformDesign2008/TIM2... · 2008. 10. 28. · © 2008 Silicon Hive BV Silicon Hive BV High Tech Campus 43, 5656

Rules and Procedures for IMI Calls for proposals · Rules and Procedures for IMI Calls for proposals IMI Webinar • 09 & 13 January 2017 . 1. Introducing IMI 2. Participation rules

Phase Change Metallic Alloy TIM2 Performance, Reliability ...enerdynesolutions.com/downloads/atw_presentation_2007.pdf · Phase Change Metallic Alloy TIM2 Performance, Reliability

IMI Graham Hughes

Distributor Imi

IMI plcIMI plc Fluid PowerFluid Power/media/Files/I/IMI/presentation/2010/08-FP... · IMI plcIMI plc Fluid PowerFluid Power October 2010October 2010. IMI Fl id PIMI Fluid Power Roy

IMI plc 2017 Preliminary Results reports/Presentations...5 IMI plc 2017 Preliminary Results £m Revenue IMI Critical Engineering 648 (3) 645 0% -6% 651 40 (5) 686 IMI Precision Engineering

imi mHealth Service

IMI plc/media/Files/I/IMI/annual-reports/imi-plc... · IMI Precision Engineering specialises in the design and manufacture of motion and fluid control technologies wherever precision,

glp2 - IMI

IMI-Abril 07

Engineering IMI CCIja.imi-critical.com/Brands/PublishingImages/Pages/IMI-CCI/IMI_CCI... · IMI CCI IMI CCI was founded upon core engineering problem-solving principles, from which